Form 8-A12B Polaryx Therapeutics,

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-A

 

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES

PURSUANT TO SECTION 12(b) OR 12(g) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

Polaryx Therapeutics, Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

Nevada		47-3393659
(State of Incorporation or Organization)		(I.R.S. Employer Identification No.)
South Tower, 140 E Ridgewood Avenue, Suite 415 Paramus, NJ		07652
(Address of Principal Executive Offices)		(Zip Code)

 

Securities to be registered pursuant to Section 12(b) of the Act:

 

Title of Each Class		Name of Each Exchange on Which
to be so Registered		Each Class is to be Registered
Common Stock, par value $0.0001 per share		The Nasdaq Stock Market LLC

 

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), please check the following box. ☒ 

 

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box. ☐

 

If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ☐

 

Securities Act registration statement or Regulation A offering statement file number to which this form relates: 333-291681

 

Securities to be registered pursuant to Section 12(g) of the Act: None.

 

 

 

Item 1. Description of Registrant’s Securities to be Registered

 

The securities to be registered hereby are shares of common stock, par value $0.0001 per share (the “Common Stock”), of Polaryx Therapeutics, Inc. (the “Registrant”). The information required by this Item 1 is incorporated herein by reference to the information set forth under the heading “Description of Capital Stock” contained in the Registrant’s Registration Statement on Form S-1 (File No. 333-291681) initially filed with the U.S. Securities and Exchange Commission on November 21, 2025 (as amended from time to time, the “Registration Statement”). The description of the Common Stock included in any form of prospectus subsequently filed by the Registrant pursuant to Rule 424(b) under the Securities Act of 1933, as amended, that constitutes part of the Registration Statement, shall also be deemed to be incorporated herein by reference.

 

Item 2. Exhibits 

 

In accordance with the “Instructions as to Exhibits” section of Form 8-A, no exhibits are required to be filed as part of this registration statement because no other securities of the Registrant are registered on The Nasdaq Stock Market LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

 

	Polaryx Therapeutics, Inc.
	By:	/s/ Alex Yang
	Name:	Alex Yang
	Title:	Chief Executive Officer

 

Date: January 27, 2026

 

 

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Wedbush Rings the Cboe Closing Bell, Celebrating a Longstanding Partnership and a Shared Commitment to Market Innovation
• DSFederal Awarded NASA SEWP VI Contracts in Both Enterprise and Mission IT Categories
• Outliyr's Independent Spectrometer Tests Find Popular Red Light Therapy Devices Delivering From 67 Percent to Nearly Triple Their Advertised Power